Results from a large European randomized controlled trial found that PSA as a primary screening test in men aged 55 to 69 years of age (followed by prostate biopsies for adults with elevated PSA) significantly reduced prostate cancer mortality (rate ratio = 0.80 (95% CI, 0.72–0.89). This evidence concerns the gene KLK3 and Familial prostate cancer.